EDCTP welcomes G8 support for HIV/AIDS vaccine developmentJune 11, 2004On 10th June 2004 during this year's summit in Sea Island, Georgia, the G8 Leaders called for the establishment of a Global HIV Vaccine Enterprise: a virtual consortium to accelerate HIV vaccine development by enhancing coordination, information sharing, and global collaboration. The EDCTP is pleased to see this expression of support and commitment to accelerating the research on and availability of a vaccine against HIV, one of the major impediments today to sustainable development of underprivileged countries. The European and Developing Countries Clinical Trials Partnership (EDCTP) believes that critical impediments to development such as the ones inflicted by HIV/AIDS, must be addressed by having the Developing Countries benefit from both the tools resulting from research (based on their public health needs), and the systems which they have acquired to assess those tools independently. The renewed emphasis about HIV expressed by the G8 Leaders is welcome, timely and only too needed. At the same time, we must not forget that the same challenges are being faced with tuberculosis and malaria, as well as other, more neglected causes of illness and poverty in the developing world. The EDCTP strongly believes that ultimately the outcome of this initiative and others will depend on the ownership and commitment to this vision by the partners, and by having the concerned countries play a central role. Adapted interventions are essential to reduce the burden caused by these diseases. Current approaches to vaccine development suffer from common problems and shortcomings, which are shared by all of these diseases. The EDCTP believes that a common, coordinated approach will benefit and expedite developments in general (i.e. capacities and methodologies). There are today insufficient capacities and overall capabilities to test products clinically in high-burden countries. The EDCTP upholds high scientific and ethical standards for the conduct of clinical studies, which can be broadly applied to the assessment of different interventions and diseases. The EDCTP is poised to contribute to the assessment of candidate interventions, such as a vaccine for HIV, by providing a platform to accelerating the process and acting as a partner, facilitator and focused clinical trials service provider in Developing Countries. | |||||||||||||||||||||
|
Related HIV Current Events and HIV News Articles Pneumococcal vaccine does not appear to protect against pneumonia Commonly used pneumococcal polysaccharide vaccines do not appear to be effective for preventing pneumonia. Prolonged nevirapine in breast-fed babies prevents HIV infection but leads to drug-resistant HIV Babies born to HIV-positive mothers and given the antiretroviral drug nevirapine through the first six weeks of life to prevent infection via breast-feeding are at high risk for developing drug-resistant HIV if they get infected anyway, a team of researchers report. Family rejection of LGB children linked to poor health in early childhood For the first time, researchers have established a clear link between family rejection of lesbian, gay and bisexual (LGB) adolescents and negative health outcomes in early adulthood. May hepatic granulomas be part of the histological spectrum of chronic hepatitis C? While older large series of patients with hepatic granulomas have found sarcoidosis and tuberculosis to be the most common causes of hepatic granulomas, recent works have noted some patients with chronic hepatic C and hepatic granulomas and no other obvious associations. Using math to understand hep. C: Patterns paint picture of who will respond to treatment Genetic patterns are like the tea leaves in the bottom of a cup for predicting which patients are likely to respond to medical therapy for life-threatening viruses such as hepatitis C, Saint Louis University researchers have discovered. Cell phones using lens-free imaging promise to improve health monitoring Cell phones have already revolutionized the way people around the world communicate and do business. Thanks to advances being made at UCLA, they are about to do the same thing for medicine. Male Circumcision May Decrease Risk of HPV Infection and Cervical Cancer Two new studies suggest that male circumcision may assist in the prevention of human papillomavirus (HPV) infection, particularly infection with the high-risk subtypes associated with cervical, penile, and other cancers. Circumcision Reduces the Risk of HIV Infection in Heterosexual U.S. Men A new U.S. study has found that being circumcised significantly reduced the risk of HIV infection in heterosexual African American men known to have been exposed to the virus. MU Researcher Refining Synthetic Molecules to Prevent HIV Resistance Evolving HIV viral strains and the adverse side effects associated with long-term exposure to current treatments propel scientists to continue exploring alternative HIV treatments. UIC researchers hunting drugs for devastating parasitic disease Hundreds of millions of people, mainly in developing countries, are disabled by infectious diseases, according to the World Health Organization. More HIV Current Events and HIV News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||